Who founded Adaptilens?

Adaptilens was founded by Liane Clamen in 2019.

Who are Adaptilens's investors?

Adaptilens's investors include Pillar VC.

How much funding has Adaptilens raised?

Adaptilens has disclosed $27.7M raised across 4 of its 6 known rounds.

Where is Adaptilens headquartered?

Adaptilens is headquartered in Chestnut Hill, US.

Adaptilens

Chestnut Hill, US · Founded 2019 · 2 known investors

Find your way into Adaptilens

Paths you didn't know you had: your email and LinkedIn already hold routes to the Adaptilens team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Adaptilens develops a biomimetic accommodating intraocular lens (A-IOL) for cataract and vision correction, an ophthalmic medical device. The company's work centers on IOL research, development, and clinical studies.

Biotech Hardware Healthtech Medical Devices

Founders & leadership

Adaptilens was founded in 2019 by Liane Clamen.

Liane Clamen Founder and CEOLiane Clamen completed her MD and BA at Harvard University and trained in ophthalmology at Massachusetts Eye and Ear. She has invented multiple ophthalmic medical devices, including a punctal plug drug delivery system and an anterior capsulotomy device, and is the founder of Adaptilens, which develops an accommodating intraocular lens.

Board

Jamie Goldstein Board directorFounding/Managing Partner at Pillar VC

John AndresBoard director

Terry KimBoard director

William SheaBoard director

Robert DorisBoard director

Investors · 2

Pillar VC✓ confirmed by AdaptilensBoston · $50K – $4M

How we know: Pillar VC's portfolio page · the company's own site · a partner's Signal profile · board seat on SEC Form D · funding news · prweb.com · Not right? Tell us

Also in the syndicate · 1

Accanto Partners

Funding

SEC filings, press & company announcements

$27.7M disclosed across 4 of 6 rounds · 2020–2026

Undisclosed amountSeries AMay 2026
Source ↗
$17.5MSeries AApr 2024 · 2 sources
Source ↗
$1.6Mseed fundingNov 2020 · 2 sources
Pillar VC (lead), Accanto Partners
Source ↗

▶$7MraisedMay 2024 · 12 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Jamie GoldsteinDirector
C. Gianna LucaDirector
William SheaDirector
Liane ClamenExecutive Officer, Director

Offering amount: $16M
Amount sold: $7M
Proceeds to insiders: $300K
First sale: Apr 2024
Incorporated: Corporation, Delaware, 2024
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.6MraisedJun 2023 · 12 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

John AndresDirector
Terry KimDirector
William SheaDirector
Robert DorisDirector
Liane ClamenExecutive Officer, Director
Jamie GoldsteinDirector

Offering amount: $1.6M
Amount sold: $1.6M
First sale: Mar 2023
Incorporated: Limited Liability Company, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Adaptilens do?: Adaptilens develops a biomimetic accommodating intraocular lens (A-IOL) for cataract and vision correction, an ophthalmic medical device. The company's work centers on IOL research, development, and clinical studies.
Who founded Adaptilens?: Adaptilens was founded by Liane Clamen in 2019.
Who are Adaptilens's investors?: Adaptilens's investors include Pillar VC.
How much funding has Adaptilens raised?: Adaptilens has disclosed $27.7M raised across 4 of its 6 known rounds.
Where is Adaptilens headquartered?: Adaptilens is headquartered in Chestnut Hill, US.